Pancreatic Cancer Research

ResearcherSouthern University of Science and TechnologyActive in the last 2 years

Siim Pauklin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8367-3670; OpenAlex author ID A5000749022. Sources: OpenAlex.

Their work

Papers
12 (first author 4, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
9
Papers, trials and grants by year

2020: 1 paper · 2021: 5 papers · 2022: none · 2023: 2 papers · 2024: 3 papers · 2025: 1 paper

Papers 12

  1. GluProRS Inhibition Abolishes Cancer Stem Cells in Pancreatic Cancer by Inducing the Integrated Stress Response and Countering TGFβ/Activin-SMAD2/3-HIF1A Last author DOI 10.21203/rs.3.rs-6672561/v1↗
  2. BRD9-SMAD2/3 Orchestrates Stemness and Tumorigenesis in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1053/j.gastro.2023.09.021↗
  3. High-dimensional mass cytometry reveals stemness state heterogeneity in pancreatic ductal adenocarcinoma Last author DOI 10.1101/2024.02.27.582358↗
  4. Quantitative secretomics identifies ligand-receptor pairs in pancreatic cancer that mediate bidirectional crosstalk between cancer stem cells and nociceptors Last author DOI 10.21203/rs.3.rs-3994602/v1↗
  5. KMT2A associates with PHF5A-PHF14-HMG20A-RAI1 subcomplex in pancreatic cancer stem cells and epigenetically regulates their characteristics. Last author DOI 10.1038/s41467-023-41297-4↗
  6. BAZ2A-SUV39H1-SMAD2/3-OCT4 regulates stemness, cell cycle exit and chemoresistance in pancreatic ductal adenocarcinoma Last author DOI 10.21203/rs.3.rs-3570401/v1↗
  7. TGFB1/INHBA Homodimer/Nodal-SMAD2/3 Signaling Network: A Pivotal Molecular Target in PDAC Treatment. First author DOI 10.1016/j.ymthe.2021.01.002↗
  8. Extracellular vesicles in pancreatic cancer progression and therapies. First author DOI 10.1038/s41419-021-04258-7↗
  9. PAF1 Regulates the Stemness of Pancreatic Cancer Stem Cells. Last author DOI 10.1053/j.gastro.2021.01.201↗
  10. Mechanisms of Cancer Cell Death: Therapeutic Implications for Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/cancers13194834↗
  11. Pancreatic Cancer Microenvironment and Cellular Composition: Current Understandings and Therapeutic Approaches. First author DOI 10.3390/cancers13195028↗
  12. Molecular Therapeutics of Pancreatic Ductal Adenocarcinoma: Targeted Pathways and the Role of Cancer Stem Cells. Last author DOI 10.1016/j.tips.2020.09.008↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chao‐Hui Chang · 5 shared papers, 2020–2025 · strength 1.04
  2. Mai Abdel Mouti · 5 shared papers, 2021–2024 · strength 1.02
  3. Stefania Militi · 5 shared papers, 2023–2025 · strength 0.94
  4. Yuliang Feng · 2 shared papers, 2021–2024 · strength 0.38
  5. Linh-Huyen Truong · 1 shared paper, 2021 · strength 0.28
  6. Hannah Pook · 1 shared paper, 2021 · strength 0.28
  7. Egle-Helene Ervin · 1 shared paper, 2024 · strength 0.23
  8. Andrei-Florian Stoica · 1 shared paper, 2020 · strength 0.19
  9. Chang‐Il Hwang · 1 shared paper, 2023 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.